Description: HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Home Page: www.hookipapharma.com
HOOK Technical Analysis
350 Fifth Avenue
New York,
NY
10118
United States
Phone:
431 890 6360
Officers
| Name | Title |
|---|---|
| Mr. Joern Aldag | CEO & Director |
| Dr. Reinhard Kandera Ph.D. | CFO & Director |
| Prof. Rolf M. Zinkernagel M.D., Ph.D. | Co-Founder |
| Mr. Andreas Bergthaler | Co-Founder |
| Mr. Lukas Flatz | Co-Founder |
| Ms. Christine D. Baker M.B.A. | Chief Operating Officer |
| Dr. Klaus Orlinger Ph.D. | Chief Scientific Officer |
| Ms. Marine Popoff | Communications & Investor Relations Mang. |
| Mr. Matthew L. S. Beck | Exec. Director of Investor Relations |
| Mr. Michael Szumera | Exec. Director of Communications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.379 |
| Price-to-Sales TTM: | 4.1011 |
| IPO Date: | 2019-04-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 131 |